The application of a 1 H NMR spectroscopy based screening method for determining the use of two widely available analgesics (acetaminophen and ibuprofen) in epidemiologic studies has been investigated. We used samples and data from the cross-sectional INTERMAP Study involving participants from Japan (n=1,145), China (n=839), UK (n=501) and USA (n=2,195). An orthogonal projection to latent structures discriminant analysis (OPLS-DA) algorithm with an incorporated Monte Carlo re-sampling function was applied to the NMR dataset to determine which spectra contained analgesic metabolites. OPLS-DA pre-processing parameters (normalization, bin width, scaling and input parameters) were assessed systematically to identify an optimal acetaminophen prediction model. Subsets of INTERMAP spectra were examined to verify and validate the presence/ absence of acetaminophen/ibuprofen based on known chemical shift and coupling patterns. The optimized and validated acetaminophen model correctly predicted 98.2% and the ibuprofen model correctly predicted 99.0 % of the urine specimens containing these drug metabolites. The acetaminophen and ibuprofen models were subsequently used to predict the presence/absence of these drug metabolites for the remaining INTERMAP specimens. The acetaminophen model identified 415 of 8,436 spectra containing acetaminophen metabolites while the ibuprofen model identified 245 of 8,604 spectra containing ibuprofen metabolites from the global dataset. The NMRbased metabolic screening strategy provides a new objective approach for evaluation of self-reported medication data and is extendable to other aspects of population xenometabolome profiling.